Kisqali

Save as Favorite
Sign in to receive recommendations (Learn more)

Kisqali (chemical name: ribociclib, formerly called LEE011) is approved by the U.S. Food and Drug Administration (FDA) to:

  • be used in combination with an aromatase inhibitor to treat advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy yet in premenopausal, perimenopausal, and postmenopausal women; premenopausal and perimenopausal women treated with Kisqali also should be treated with a luteinizing hormone-releasing hormone agonist, such as Zoladex (chemical name: goserelin), to suppress ovarian function
  • be used in combination with Faslodex (chemical name: fulvestrant) to treat advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy yet, or has grown while being treated with a different hormonal therapy, in postmenopausal women

Kisqali is a pill taken by mouth.

In this section you can learn more about:


Was this article helpful? Yes / No

Supportpeopleyellow banner mini
Back to Top